Corrigendum: Discovery of spirooxindole-derived small-molecule compounds as novel HDAC/MDM2 dual inhibitors and investigation of their anticancer activity

Front Oncol. 2023 Aug 25:13:1259550. doi: 10.3389/fonc.2023.1259550. eCollection 2023.

Qian Zhao¹, Shan-Shan Xiong², Can Chen^{3

4}, Hong-Ping Zhu^{1

5}, Xin Xie¹, Cheng Peng¹, Gu He², Bo Han¹

¹ State Key Laboratory of Southwestern Chinese Medicine Resources, Hospital of Chengdu University of Traditional Chinese Medicine, School of Basic Medical Sciences, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
² Department of Dermatology and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
³ School of Pharmacy, Chengdu Medical College, Chengdu, China.
⁴ The First Affiliated Hospital, Chengdu Medical College, Chengdu, China.
⁵ Antibiotics Research and Re-evaluation Key Laboratory of Sichuan Province, Sichuan Industrial Institute of Antibiotics, Chengdu University, Chengdu, China.

Abstract

[This corrects the article DOI: 10.3389/fonc.2022.972372.].

Keywords: MDM2 inhibitors; anticancer; dual inhibitors; histone deacetylase inhibitors; multitarget drugs; spirooxindole.